Amber is an experienced and proven leader in driving therapy development and delivery to address unmet medical needs. She currently serves as CEO of Epic Bio and serves as an independent Board Director for other companies.Amber served as the CEO and President of Ohana Biosciences and previously led Adverum Biotechnologies (NASDAQ:ADVM), a company focused on gene therapy treatments for rare diseases and diseases of the eye. Prior to her role at Adverum, she sold Cardiokine, a specialty pharmaceutical company focused on developing medicines to treat and prevent heart failure and related cardiovascular indications. Previously, Amber was with GlaxoSmithKline for 25 years and as a member of the GSK R&D executive team she was responsible for planning and managing drug development projects and clinical trials with over 30,000 active patients around the world. Concurrent with her industry roles, Amber led and continues to lead a Foundation focused on improving the care for patients with Adrenoleukodystrophy. Her diverse experiences and delivery of leading edge solutions honed a critical entrepreneurial eye and in-depth understanding of the dynamics of therapy development and commercialization. Amber holds a Bachelor's degree from Temple University and PhD in Mathematics from Bryn Mawr College. Honors include being inducted into Temple University's League of Entrepreneurial Women Hall of Fame. Other roles include serving as an Independent Director on biotech boards and serving on the Advisory Board for the Dean of Drexel University's School of Public Health and serving as a trustee for the Lankenau Institute for Medical Research.